Form 6-K Centogene N.V. For: May 19

May 19, 2022 6:31 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the date of May 19, 2022

 

Commission File Number 001-39124

 


Centogene N.V.
(Translation of registrant's name into English)

 

Am Strande 7
18055 Rostock

Germany
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F..X.. Form 40-F.....


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

Centogene N.V.

 

On May 19, 2022, Centogene N.V. issued a press release titled “CENTOGENE to Present at the H.C. Wainwright Global Investment Conference”.

 

A copy of the announcement is attached hereto as Exhibit 99.1.

 

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: May 19, 2022

 

  CENTOGENE N.V.
       
       
  By: /s/ Miguel Coego Rios
    Name: Miguel Coego Rios
    Title: EVP Finance & Legal and Interim CFO

 

 

 

Exhibit Index

 

Exhibit Description of Exhibit
   
99.1 Announcement dated May 19, 2022

 

 

Exhibit 99.1

 

 

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

 

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 19, 2022 (GLOBE NEWSWIRE)

 

Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced that Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites investors to participate via virtual one-on-one meetings.

 

Please see additional details below:

 

H.C. Wainwright Global Investment Conference (Hybrid Conference)
 
Speakers: Kim Stratton – CEO of Centogene N.V.
   
  Miguel Coego – CFO (ai) of Centogene N.V.
   
Format: Company Presentation & one-on-one meetings
   
Webcast: Registration Link: https://hcwevents.com/globalconference/
   
  Recording* will be available starting Tuesday, May 24, 2022, at 07:00 a.m. ET via  
   
  CENTOGENE’s investor relations website at https://centogene.gcs-web.com/events/event-details/hc-wainwright-global-investment-conference

 

*A replay will be available for 90 days following the presentation.

 

Please contact your representative at H.C. Wainwright to schedule a virtual one-on-one meeting with CENTOGENE during the conference. For information about the H.C. Wainwright Global Investment Conference, please refer to the events website (https://hcwevents.com/globalconference/). 

 

About CENTOGENE

 

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical, genetic, and multiomic data to diagnose, understand, and treat rare diseases. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge and data. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository of over 650,000 individuals representing over 120 different countries.

 

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows for better identification and stratification of patients and their underlying diseases to enable and accelerate discovery, development, and access to orphan drugs. As of December 31, 2021, the Company collaborated with over 30 pharmaceutical partners.

 

Follow us on LinkedIn 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the U.S. federal

 

 

 

 

 

securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE’s specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

 

Media Contact:  

CENTOGENE  

Lennart Streibel 

Investor Relations 

[email protected]  

 

Ben Legg 

Corporate Communications 

[email protected]  

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings